Greater regulatory clarity given
Destiny have announced an update on the discussions with the FDA on the Phase 3 development plans...
Read moreOutflows slow in Q1 but markets drive AUM lower
AUM fell £3.17bn or 14% over Q1 of FY23, from £22.12bn on 31 Mar 22 to £18.95bn on 30 Jun 22. This...
Read moreNet inflows strengthen again, but market falls reduce FUM
Two themes jump out at us at the close of FY22 (to 30 Jun 22). First, in the first full FY of CEO...
Read moreFY 2022 Final Results
RUA Life Sciences’ FY 2022 results included total revenues that increased by 6% on the previous...
Read moreA year of strategic focus
2021 proved to be an eventful year for MCH. The new Board sought to re-engineer the Group into a...
Read moreFY22 first half trading update: supply chain pressure
In a trading update for the half year to 30 June 2022, Mpac reports that supply chain difficulties...
Read more
Factory extension open to satisfy demand
A site visit to Burton-on-Trent for the official opening of the new manufacturing facility proved...
Read moreNo material outflows but markets impact AUM
On 30 June 2022 (end-Q3 of Impax’s FY22), AUM totalled £34.5bn, 9% down on the end-Q2 AUM of...
Read moreCollaboration to develop poultry red mite vaccine
ECO Animal Health has established a research collaboration with Moredun Research Institute aimed at...
Read moreFY22 results in line: FY23 emphasis on Vaping
For the year to 31 March 2022, Supreme PLC reported revenue of £130.8m, +7.0%YoY, gross profit of...
Read moreA useful addition to XF-73’s profile
Destiny have announced a new XF-73 research programme on the prevention of oral mucositis (OM) in...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
